In this 52-week phase 3 trial supported by AMR Clinical sites, fixed-dose insulin efsitora was noninferior to daily glargine for A1C reduction in insulin-naïve patients. Participants on efsitora had fewer hypoglycemic events, fewer dose adjustments, and lower total insulin exposure compared to those on glargine.
Read this publication to explore:
- How fixed-dose weekly efsitora compares to daily glargine
- Glycemic control, hypoglycemia, and insulin dose outcomes
- Potential advantages for simplifying insulin initiation